Not all products are available in all regions. GDPR Statement (last updated: May 2018) | California Transparency in Supply Chains Act | Declaration for California Compliance Law. Any person depicted in such photographs is a model. Photos displayed are for illustrative purposes only. Your use of this website and the information contained herein is subject to our Website Terms and Conditions and Privacy Policy: US Citizens | Non-US Citizens.
#Rapid diagnostics registration
The products and information contained herewith may not be accessible in all countries, and Abbott takes no responsibility for such information which may not comply with local country legal process, regulation, registration and usage.
This website is governed by applicable U.S. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. Through the JPIAMR, IDRC has partnered with 18 other donor agencies to fund innovative research projects on diagnostics and surveillance strategies, tools, and technologies that can be used to detect and monitor antimicrobial resistance in human, animal, and environmental settings, particularly in low and middle-income countries.©2022 Abbott. This is one of five IDRC-funded projects developed through the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR), an international platform that coordinates global funding to support collaborative research and action on antimicrobial resistance. The project is establishing a partnership with a Canadian private sector company that will provide technical, commercial, and legal expertise to support the downstream licensing and commercialization of the technology. The project will involve an international and multidisciplinary team of collaborators from Thailand, France, Poland, and Canada, with expertise in proteogenomics, bacteriology, molecular epidemiology, and clinical microbiology. Once developed and validated, the project will undertake real-world testing in clinical laboratories. This project aims to develop and evaluate new diagnostics technology that will allow clinicians to identify a pathogen and produce a clinical profile of its susceptibility to clinical therapies in less than one hour. However, cost and availability issues have prevented clinicians from applying these technologies towards improving the clinical management of blood infections. With advances to cutting-edge molecular diagnostic technologies like mass spectrometry, the time required to identify an infectious agent has been drastically reduced. The considerable time it takes to identify and test for antibiotic-resistant infections results in critical delays to administer appropriate antimicrobial therapy and it has a detrimental effect on the clinical outcome of patients. Globally, bloodstream infections are a significant cause of clinical morbidity and mortality estimated to cause several hundred thousand deaths annually worldwide.
0 kommentar(er)
